tetano
Editor, Senior Moderator
J Med Virol
. 2024 Jun;96(6):e29740.
doi: 10.1002/jmv.29740. Risks of cutaneous immune-related adverse events in long COVID: Multinational cohort studies in South Korea, Japan, and the UK
Hyejun Kim[SUP] 1 2 [/SUP], Seoyeon Kyung[SUP] 1 3 [/SUP], Jaeyu Park[SUP] 1 3 [/SUP], Hojae Lee[SUP] 1 3 [/SUP], Myeongcheol Lee[SUP] 1 3 [/SUP], Lee Smith[SUP] 4 [/SUP], Masoud Rahmati[SUP] 5 6 7 [/SUP], Ju-Young Shin[SUP] 8 [/SUP], Jiseung Kang[SUP] 9 10 [/SUP], Louis Jacob[SUP] 11 12 13 [/SUP], Nikolaos G Papadopoulos[SUP] 14 15 [/SUP], Sang Youl Rhee[SUP] 1 3 16 [/SUP], Jinseok Lee[SUP] 17 [/SUP], Hyeon Jin Kim[SUP] 1 3 [/SUP], Hayeon Lee[SUP] 1 17 [/SUP], Dong Keon Yon[SUP] 1 3 18 [/SUP]
Affiliations
Previous research has not investigated the persistent cutaneous immune-related adverse events (cirAEs) related to long COVID to investigate the long-term sequelae. This multinational study, using a propensity-matched overlap weighting method, utilizes large national claims-based cohorts, using ICD-10 code diagnosis, focusing on patients aged ≥20 years from three countries: South Korean, Japanese, and the British cohorts. To estimate the risk of cirAEs in long COVID, the persistence or emergence of cirAEs occurring 4 weeks after the initial SARS-CoV-2 infection, we employed a Cox proportional hazard regression model. The Korean cohort (n = 5,937,373; mean age 49.2 years [SD: 13.2]), the Japanese cohort (n = 4,307,587; 42.5 years [13.6]), and the UK cohort (n = 395,435; 71.0 years [8.07]) were presented. An increased risk of cirAEs in long COVID was observed (HR, 1.10; 95% CI, 1.06-1.14) in Korean cohort, while a similar association was observed in Japanese and UK cohorts. The long-term risk of cirAEs in long COVID was higher in more severe COVID-19 cases (1.31; 1.22-1.39). Unlike the increased risk of cirAEs in long COVID, COVID-19 vaccination attenuated the risk, especially with two or more doses (1.03; 0.95-1.11) or heterologous regimens (0.98; 0.76-1.27). The time attenuation effect indicated a sustained risk for up to 6 months postinfection (<3 months: 1.13 [1.07-1.19]; 3-6 months: 1.14 [1.06-1.22]). SARS-CoV-2 infection is associated with an increased risk of cirAEs in the aspect of long COVID. Vaccination might reduce this risk, highlighting the need for preventive strategies in long COVID management.
Keywords: COVID‐19; SARS‐CoV‐2; cirAEs; long COVID; multi‐national; vaccination.
. 2024 Jun;96(6):e29740.
doi: 10.1002/jmv.29740. Risks of cutaneous immune-related adverse events in long COVID: Multinational cohort studies in South Korea, Japan, and the UK
Hyejun Kim[SUP] 1 2 [/SUP], Seoyeon Kyung[SUP] 1 3 [/SUP], Jaeyu Park[SUP] 1 3 [/SUP], Hojae Lee[SUP] 1 3 [/SUP], Myeongcheol Lee[SUP] 1 3 [/SUP], Lee Smith[SUP] 4 [/SUP], Masoud Rahmati[SUP] 5 6 7 [/SUP], Ju-Young Shin[SUP] 8 [/SUP], Jiseung Kang[SUP] 9 10 [/SUP], Louis Jacob[SUP] 11 12 13 [/SUP], Nikolaos G Papadopoulos[SUP] 14 15 [/SUP], Sang Youl Rhee[SUP] 1 3 16 [/SUP], Jinseok Lee[SUP] 17 [/SUP], Hyeon Jin Kim[SUP] 1 3 [/SUP], Hayeon Lee[SUP] 1 17 [/SUP], Dong Keon Yon[SUP] 1 3 18 [/SUP]
Affiliations
- PMID: 38874226
- DOI: 10.1002/jmv.29740
Previous research has not investigated the persistent cutaneous immune-related adverse events (cirAEs) related to long COVID to investigate the long-term sequelae. This multinational study, using a propensity-matched overlap weighting method, utilizes large national claims-based cohorts, using ICD-10 code diagnosis, focusing on patients aged ≥20 years from three countries: South Korean, Japanese, and the British cohorts. To estimate the risk of cirAEs in long COVID, the persistence or emergence of cirAEs occurring 4 weeks after the initial SARS-CoV-2 infection, we employed a Cox proportional hazard regression model. The Korean cohort (n = 5,937,373; mean age 49.2 years [SD: 13.2]), the Japanese cohort (n = 4,307,587; 42.5 years [13.6]), and the UK cohort (n = 395,435; 71.0 years [8.07]) were presented. An increased risk of cirAEs in long COVID was observed (HR, 1.10; 95% CI, 1.06-1.14) in Korean cohort, while a similar association was observed in Japanese and UK cohorts. The long-term risk of cirAEs in long COVID was higher in more severe COVID-19 cases (1.31; 1.22-1.39). Unlike the increased risk of cirAEs in long COVID, COVID-19 vaccination attenuated the risk, especially with two or more doses (1.03; 0.95-1.11) or heterologous regimens (0.98; 0.76-1.27). The time attenuation effect indicated a sustained risk for up to 6 months postinfection (<3 months: 1.13 [1.07-1.19]; 3-6 months: 1.14 [1.06-1.22]). SARS-CoV-2 infection is associated with an increased risk of cirAEs in the aspect of long COVID. Vaccination might reduce this risk, highlighting the need for preventive strategies in long COVID management.
Keywords: COVID‐19; SARS‐CoV‐2; cirAEs; long COVID; multi‐national; vaccination.